Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503871 | 0.93 | MEN1 (0.48) | KMT2AMEN1MAPTFFAR1PTGES | |
| SCHEMBL503499 | 0.93 | MDM2 (0.45) | KMT2AMEN1MAPTFFAR1MDM2 | |
| SCHEMBL503625 | 0.92 | USP14 (0.44) | KMT2AMEN1MAPTFFAR1PTGES | |
| SCHEMBL504142 | 0.90 | MEN1 (0.44) | KMT2AMEN1MAPTFFAR1PTGES | |
| SCHEMBL503612 | 0.88 | NPC1 (0.41) | KMT2AMEN1PTGESMDM2MCL1 | |
| SCHEMBL503554 | 0.88 | MEN1 (0.45) | KMT2AMEN1FFAR1PTGESMDM2 | |
| SCHEMBL333231 | 0.86 | MEN1 (0.48) | KMT2AMEN1MAPTPTGESKDM4E | |
| SCHEMBL503848 | 0.85 | MAPT (0.45) | KMT2AMEN1MAPTFFAR1MDM2 | |
| SCHEMBL503872 | 0.85 | USP14 (0.48) | KMT2AMEN1MAPTPTGESKDM4E | |
| SCHEMBL334235 | 0.85 | BCL2 (0.42) | KMT2AMEN1MAPTPTGESMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| WO-2010076566-A2 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | KMT2A 1783/4885MEN1 2934/4885MAPT 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.